Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.34 |
| ▸ | PTGIR | P43119 | 4/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18938837 | 1.00 | LMNA (0.43) | LMNAKMT2AALDH1A1CYP3A4MCL1 | |
| SCHEMBL20523919 | 0.92 | LMNA (0.53) | LMNAKMT2AALDH1A1CYP3A4POLB | |
| SCHEMBL20523784 | 0.90 | LMNA (0.56) | LMNAKMT2AALDH1A1POLBHPGD | |
| SCHEMBL3363757 | 0.90 | LMNA (0.56) | LMNAKMT2AALDH1A1POLBHPGD | |
| SCHEMBL2908261 | 0.76 | ALDH1A1 (0.46) | LMNAALDH1A1CYP3A4POLB | |
| SCHEMBL27469061 | 0.75 | LMNA (0.67) | LMNAALDH1A1PTGIRPTGDRPOLB | |
| SCHEMBL11239739 | 0.74 | LMNA (0.66) | LMNAALDH1A1POLB | |
| SCHEMBL27496508 | 0.74 | MCL1 (0.46) | LMNAKMT2AALDH1A1MCL1 | |
| SCHEMBL12284997 | 0.73 | LMNA (0.59) | LMNAALDH1A1POLB | |
| SCHEMBL6890414 | 0.72 | MCL1 (0.43) | KMT2AMCL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | LMNA 4878/4885KMT2A 4104/4885ALDH1A1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.